补体，ALS

APLS study did not meet its primary endpoint of the Combined Assessment of Function and Survival (CAFS) rank score at Week 52. 

The study also did not meet key secondary efficacy endpoints.

APLS to discontinue the development of systemic pegcetacoplan for ALS$Apellis制药(APLS)$